Form 990 for tax year 2024
Filed by LMSARCOMA DIRECT RESEARCH FOUNDATION.
Totals
- Total revenue
- $1,465,263
- Total expenses
- $330,368
- Contributions and grants received
- $1,445,845
- Grants paid
- $292,000
- Program service revenue
- $0
- Investment income
- $19,418
- Other revenue
- $0
- Total assets, end of year
- $2,077,910
- Total liabilities, end of year
- $1,070
- Net assets or fund balances, end of year
- $2,076,840
- Program services expenses (Part IX)
- $322,946
- Management and general expenses
- $7,422
- Fundraising expenses
- $0
- Program service expenses (Part III)
- $322,946
Program services were 97.8% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.
Line items
Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.
Revenue
Part VIII, the statement of revenue.
-
1a · Federated campaigns
$0
-
1b · Membership dues
$0
-
1c · Fundraising events
$0
-
1d · Related organizations
$0
-
1e · Government grants (contributions)
$0
-
1f · All other contributions, gifts and grants
$1,445,845
-
1g · Noncash contributions included above
$0
-
3 · Investment income
total $19,418 · related or exempt $19,418 · unrelated business $0 · excluded $0
-
4 · Income from investment of tax-exempt bond proceeds
total $0 · related or exempt $0 · unrelated business $0 · excluded $0
-
5 · Royalties
total $0 · related or exempt $0 · unrelated business $0 · excluded $0
-
6c · Rental income or loss
real property $0 · personal property $0
-
7c · Gain or loss
securities $0 · other assets $0
-
8a · Fundraising events: contributions included on line 1c
$0
-
11e · Other revenue, total
$0
Functional expenses
Part IX, the statement of functional expenses.
-
1 · Grants to domestic organizations and governments
total $292,000 · program services $292,000
-
5 · Compensation of officers, directors and key employees
total $0 · program services $0 · management and general $0 · fundraising $0
-
6 · Compensation of disqualified persons
total $0 · program services $0 · management and general $0 · fundraising $0
-
7 · Other salaries and wages
total $0 · program services $0 · management and general $0 · fundraising $0
-
8 · Pension plan contributions
total $0 · program services $0 · management and general $0 · fundraising $0
-
9 · Other employee benefits
total $0 · program services $0 · management and general $0 · fundraising $0
-
10 · Payroll taxes
total $0 · program services $0 · management and general $0 · fundraising $0
-
11c · Fees: accounting
total $3,300 · management and general $3,300
-
11f · Fees: investment management
total $0
-
13 · Office expenses
total $0
-
14 · Information technology
total $4,841 · program services $3,318 · management and general $1,523
-
17 · Travel
total $1,259 · program services $1,259
-
19 · Conferences, conventions and meetings
total $26,369 · program services $26,369
-
24a · Other expenses: Office Expenses
total $1,585 · program services $0 · management and general $1,585 · fundraising $0
-
24b · Other expenses: shipping and mail
total $1,014 · program services $0 · management and general $1,014 · fundraising $0
Balance sheet
Part X, book values.
-
1 · Cash, non-interest-bearing
beginning of year $258,093 · end of year $20,056
-
2 · Savings and temporary cash investments
beginning of year $657,885 · end of year $1,024,592
-
11 · Investments: publicly traded securities
end of year $1,033,262
-
17 · Accounts payable and accrued expenses
beginning of year $0 · end of year $1,070
-
29 · Capital stock, trust principal or current funds
beginning of year $0 · end of year $0
-
30 · Paid-in or capital surplus, or land, building or equipment fund
beginning of year $0 · end of year $0
-
31 · Retained earnings, endowment or other funds
beginning of year $915,978 · end of year $2,076,840
Mission and programs · 2024
Mission
To help find a cure for leiomyosarcoma by creating relationships with researchers and funding research that can lead to an effective treatment. To provide a forum for patients and care givers to share there experiences and to keep them informed of current studies.
Activities or mission (Part I)
To help find a cure for Leiomyosarcoma by creating a relationship with researchers in which we help fund projects that can lead to effective treatments. The secondary mission is to provide a forum for Patients and care givers to share information and access to the latest studies.
-
The major program is to raise funds for the researching a cure for Leio0myosarcoma, a rare cancer. Very little money is invested in seed grants to discover methods that may lead to a cure. Research is done by reputable organizations. LMSDR was able to fund 4 different research projects.
Expenses $292,000 · Grants $292,000
-
We have a Support Group Lifeline in order to serve newly diagnosed patients with information, support, guidance, and hope for treatment of their condition.
Expenses $3,318
-
LMSDR sponsors conference where researchers can collaborate with each other and presents there work to LMS patients and caregivers.
Expenses $27,628
As filed on the 2024 return.
Listed in Part VII
-
Sharon Anderson
President
- Total calculated
- $0
- Hours/week
- 10
-
Denice Brice
Secretary
- Total calculated
- $0
- Hours/week
- 2
-
Howard Smith
Dir
- Total calculated
- $0
- Hours/week
- 0
-
Edward Kurtz
Treasurer and V. President
- Total calculated
- $0
- Hours/week
- 2
Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those.
Grants on this return
-
Research project "Multi Omic profiles and invasive properties of extracellular vesicles in Leiomyosarcoma"
-
$67,000
Build an integrated multi-omic + functional validation platform using patient-derived ULMS models to identify and validate therapeutic targets, then generalize findings using public ULMS datasets.
-
$50,000
Extension of grant made in 2022. Development of an Immune Biomarker for Metastatic Disease in Retroperitoneal Leiomyosarcoma (RP LMS).
-
$25,000
Research regarding "Distribution of Novel Human Macrophage Subsets in LMS"
Provenance
- Return type
- form_990
- Tax year
- 2024
- Filed
- 14 November 2025
- IRS schema version
- 2024v5.0
- Source object
- 202621009349300947
Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.
The source document this was parsed from is served over the API, which is where bulk and document access live.